Hugo Mouquet

This study examines how SARS-CoV-2 RBD antibodies differ in function, showing that neutralizing antibodies lose effectiveness against variants but retain effector functions, while non-neutralizers remain broadly reactive but less effective overall.

The paper shows that variant-specific spike conformational dynamics influence memory B cell recruitment and antibody responses during vaccination.

This paper presents EscapeMap, a framework for predicting and designing SARS-CoV-2 variants that escape antibodies, and identifies antibody combinations less prone to simultaneous escape.

The paper identifies and functionally characterizes regulatory variants in DPP9 associated with severe COVID-19 by analyzing genetic risk factors and their impact on gene expression and immune cell function.

The paper examines neutrophil immunomodulatory properties and FcR dynamics in HIV-1 infection and therapy, finding altered cytokine production and FcR expression in PLWH.

This study shows TMPRSS2 reduces antibody binding to SARS-CoV-2 spike by altering its structure and shedding, but not virion infectivity.

The paper develops a pipeline to generate potent Affitins targeting SARS-CoV-2 spike protein RBD, achieving high neutralization potency with IC50 values as low as 0.8 pM.

The paper evaluates the neutralization activity of two new monoclonal antibodies against emerging SARS-CoV-2 variants and finds reduced efficacy against some sublineages.

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

This study identifies factors influencing DNA methylation variation in human blood, showing that cytomegalovirus infection and aging drive methylation changes, with cellular composition and DNA sequence as key predictors.

The paper identifies novel genetic and non-genetic factors associated with plasma protein levels in healthy donors, highlighting their impact on immune response variability.